Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 96 publications
Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial.
Journal: JAMA
Published: July 13, 2026
Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: February 23, 2026
Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: January 12, 2026
Posttreatment Amyloid Levels and Clinical Outcomes Following Donanemab for Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Journal: JAMA neurology
Published: October 13, 2025
Donanemab in early symptomatic Alzheimer's disease: results from the TRAILBLAZER-ALZ 2 long-term extension.
Journal: The journal of prevention of Alzheimer's disease
Published: October 10, 2025
Association between Plasma P-tau217 and Alzheimer's Copathology and Cognitive Decline in Parkinson's Disease.
Journal: Annals of neurology
Published: September 23, 2025
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6.
Journal: The journal of prevention of Alzheimer's disease
Published: June 13, 2025
Amyloid-Related Imaging Abnormalities With Donanemab in Early Symptomatic Alzheimer Disease: Secondary Analysis of the TRAILBLAZER-ALZ and ALZ 2 Randomized Clinical Trials.
Journal: JAMA neurology
Published: March 10, 2025
Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: January 02, 2025
Clinical validation of the Lilly SP-X P-tau217 assay: Performance in underrepresented cohorts.
Journal: Alzheimer's & dementia (Amsterdam, Netherlands)
Published: December 27, 2024
Key considerations for combination therapy in Alzheimer's clinical trials: Perspectives from an expert advisory board convened by the Alzheimer's drug discovery foundation.
Journal: The journal of prevention of Alzheimer's disease
Published: September 18, 2024
Last Updated: 09/26/2026